Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Background and aims Digital single-operator cholangioscopy (DSOC) enhances biliary stricture diagnosis, but the collection of quality samples can be difficult due to the small diameter of the working channel. A new DSOC (EyeMAXTM 11Fr, Micro-Tech Endoscopy, Nanjing, China) with a 2.0 mm working channel, accommodating pediatric forceps (1.6 mm), has been introduced in France. This study reports on the initial French experience.
Methods A retrospective multicenter observational study on DSOC was conducted across five endoscopy units within the CREGG (French Society of Private Hepato-Gastroenterology). Satisfaction and procedural evaluations were recorded using a visual analog scale (VAS) and compared with the SpyglassTM DS II DSOC (Boston Scientific).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients scheduled for cholangioscopy | All patients who underwent digital single-operator cholangioscopy using the new EyeMAX™ 11Fr (Micro-Tech Endoscopy, Nanjing, China) and were admitted to one of the CREGG centers between February 2024 and January 2025. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| DSOC EyeMAX 11Fr | Device | digital single-operator cholangioscopy using the new EyeMAX™ 11Fr (Micro-Tech Endoscopy, Nanjing, China) |
|
| Measure | Description | Time Frame |
|---|---|---|
| overall satisfaction with the EyeMAX 11Fr DSOC | evaluated using a VAS (ranging from 0 - not at all satisfied - to 10 - extremely satisfied) | At the end of the procedure |
| overall satisfaction with the EyeMAX 11Fr DSOC | Satisfaction with the EyeMAX 11Fr DSOC compared with the device currently available in France, the SpyGlass™ DS II DSOC. Satisfaction was categorized as better, equivalent, or worse relative to the SpyGlass™ DS II. | At the end of the procedure |
| Measure | Description | Time Frame |
|---|---|---|
| Satisfaction of introduction of the EyeMAX 11Fr into the duodenoscope's working channel | Step of the procedure evaluated using a VAS (ranging from 0 - impossible - to 10 - extremely easy) | At the end of the procedure |
| Satisfaction of the exit of the device from the working channel |
| Measure | Description | Time Frame |
|---|---|---|
| Adverse effects (AEs) and severe AEs due to ERCP | Defined and graded according to the AGREE classification | Within one month of the procedure |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
The study included all consecutive patients who were referred to one of the participating expert tertiary endoscopy units (5 centers from the CREGG - French Society of Private Hepato-Gastroenterology, in which the EyeMAX DSOC systems were made available), during the first year of availability of this device in France
Not provided
| Name | Affiliation | Role |
|---|---|---|
| David Karsenti, MD | Pôle Digestif Paris-Bercy, Clinique Paris-Bercy | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Clinique Paris-Bercy | Charenton-le-Pont | 94220 | France | |||
| Louis Pasteur Clinic |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 40808865 | Derived | Karsenti D, Sportes A, Leblanc S, Bechet S, Derman J, Fassler I, Brieau B. Contribution of the EyeMAX 11Fr (Micro-Tech) digital single-operator cholangioscope with a wide working channel: a multicenter pilot study on the first French experiences. Ther Adv Gastroenterol. 2025 Aug 12;18:17562848251360117. doi: 10.1177/17562848251360117. eCollection 2025. |
Not provided
Not provided
At this time, no decision has been made regarding the sharing of individual participant data (IPD).
This study is the first French experience with the EyeMAX™ 11Fr digital single-operator cholangioscope and has been designed as an observational study. Accordingly, IPD sharing is not currently planned as part of the initial protocol, but may be considered at a later stage.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Step of the procedure evaluated using a VAS (ranging from 0 - impossible - to 10 - extremely easy) |
| At the end of the procedure |
| Satisfaction of the biliary cannulation through the papilla | Step of the procedure evaluated using a VAS (ranging from 0 - impossible - to 10 - extremely easy) | At the end of the procedure |
| Satisfaction of the progression through the bile duct | Step of the procedure evaluated using a VAS (ranging from 0 - impossible - to 10 - extremely easy) | At the end of the procedure |
| Satisfaction of the maneuverability | Step of the procedure evaluated using a VAS (ranging from 0 - impossible - to 10 - extremely easy) | At the end of the procedure |
| Satisfaction of the ease of introducing the biopsy forceps to the target | Step of the procedure evaluated using a VAS (ranging from 0 - impossible - to 10 - extremely easy) | At the end of the procedure |
| Satisfaction of the ease of performing biopsies | Step of the procedure evaluated using a VAS (ranging from 0 - impossible - to 10 - extremely easy) | At the end of the procedure |
| image quality (definition, lens cleaning quality, and brightness) | assessed using a VAS (ranging from 0 - very poor - to 10 - exceptional) | At the end of the procedure |
| Utility of use of the harness model compared with the model fixed directly on the duodenoscope | evaluated by the question: "Does the harness facilitate handling? (Y/N)" | At the end of the procedure |
| total ERCP duration | described in minutes | At the end of the procedure |
| Total cholangioscopy duration | described in minutes | At the end of the procedure |
| Cholangioscopy success rate | Percentage of patients in whom the procedure was performed with effective bile duct visualization | At the end of the procedure |
| Number of biopsies performed | Number of bile duct biopsies performed during DSOC procedure | At the end of the procedure |
| Time required to perform biliary biopsies using DSOC | Described in minutes | At the end of the procedure |
| Malignant or benign status of the biliary stricture | The diagnosis of cholangiocarcinoma was established through biliary cytopathological examination of biopsies obtained during DSOC , biliary brushing, EUS-FNB, or surgical resection, and/or based on tumor progression observed after more than 6 months of follow-up in cases where specimens were negative for malignancy | After more than 6 months of follow-up in cases where specimens were negative for malignancy |
| Essey-lès-Nancy |
| 54270 |
| France |
| Jean Mermoz Private Hospital | Lyon | 69008 | France |
| Jules Verne Clinic | Nantes | 44300 | France |
| Arnaud Tzang Institut | Saint-Laurent-du-Var | 06700 | France |
| ID | Term |
|---|---|
| D018281 | Cholangiocarcinoma |
| D041761 | Cholecystolithiasis |
| ID | Term |
|---|---|
| D000230 | Adenocarcinoma |
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D002769 | Cholelithiasis |
| D001660 | Biliary Tract Diseases |
| D004066 | Digestive System Diseases |
| D005705 | Gallbladder Diseases |
Not provided
Not provided